Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) Ltd said that it has nearly completed the pilot run of its Amanita Muscaria-derived product Calm.
Calm, the company's flagship product, is the first legal Amanita Muscaria mushroom extract approved for sale in the US.
The Toronto-based life sciences company added that it is “ready to move forward with pre-orders” by July 19.
READ: Psyched Wellness says pilot production of its Amanita Muscaria product ‘Calm’ to start on July 7, 2022
Products are anticipated to be available to US consumers by fall 2022, it told investors.
Psyched told investors that since Calm does not require a prescription, it leaves the retail landscape open to many possibilities for distribution and listing potential.
The company is also celebrating its second anniversary, according to CEO Jeffrey Stevens.
"With today being Psyched Wellness (CSE:PSYC, OTCQB:PSYCF)' second anniversary as a company, we felt it was perfect timing to set a date for consumers in the United States to be able to pre-order Calm," Stevens said in a statement.
"It has been a long journey to get to this point, and I would like to take this opportunity to thank my co-founder, David Shisel, our team, KGK Science and Vantage Hemp for all of their hard work and commitment to get us to where we are today. The most exciting part for me is that we have just scratched the surface with respect to potential uses and delivery forms for AME-1. Stay tuned for more to come from Psyched."
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas